Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris

Juczyńska, Katarzyna; Woźniacka, Anna; Waszczykowska, Elżbieta; Danilewicz, Marian; Wągrowska-Danilewicz, Małgorzata; Żebrowska, Agnieszka

doi:10.1007/s12026-020-09122-y

Cited by 6 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytokines such as IFN and IL-4 have been shown to play a biological role through JAK proteins. JAK1, JAK3, STAT6, and IL-4 signaling pathways are also important for the differentiation and proliferation of helper T cells ( 18 ). These discoveries suggest that the JAK/STAT signaling pathway plays a significant role in the pathogenesis of pemphigus diseases.…”

Section: The Jak/stat Pathway In Aibdmentioning

confidence: 99%

“…Multiple immune mechanisms, including cellular and humoral immunity, contribute to the development of pemphigus diseases. Researches have demonstrated that serum levels of tumor necrosis factor-a (TNF-a) and several type I and II cytokines, such as IL-1b, IL-4, IL-6, IL-8, IL-10, IL-12, and IL-15, are increased in patients with PV, while levels of IFN-g are decreased (18)(19)(20). Furthermore, desmoglein (Dsg)3-reactive helper T cell (Th)1 and Th2 cells are found in patients with pemphigus disease.…”

Section: The Jak/stat Pathway In Aibdmentioning

confidence: 99%

See 1 more Smart Citation

Janus kinase inhibitors in autoimmune bullous diseases

et al. 2023

View full text Add to dashboard Cite

Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants. Additionally, the utilization of biological agents such as rituximab, omalizumab, and dupilumab is on the rise. However, effectively managing AIBD remains a challenge. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway has been implicated in various inflammatory diseases. In recent years, a range of drugs known as JAK inhibitors, which target this pathway, have been developed. Several studies have explored the efficacy and safety of JAK inhibitors for treating AIBD. Consequently, this review begins by examining the role of the JAK/STAT pathway in AIBD, summarizing the application of different JAK inhibitors in AIBD treatment, and emphasizing the importance of disease management in treating AIBD with JAK inhibitors. Furthermore, it highlights the need for a better understanding of the JAK/STAT pathway’s role in AIBD, as well as the effectiveness and safety of JAK inhibitors for treating this disease.

show abstract

Section: The Jak/stat Pathway In Aibdmentioning

confidence: 99%

Section: The Jak/stat Pathway In Aibdmentioning

confidence: 99%